Lexicon expects delay in FDA feedback on additional data for its diabetes drug
Refinitiv閱讀少於1分鐘
Lexicon Pharmaceuticals 
LXRX said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.
登入或建立一個永久免費帳戶來閱讀此新聞